All treatments
Treatment
Placebo for test product BAY 2433334 clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
This study is testing a new medication called asundexian against a standard treatment (apixaban) to see how well it prevents strokes or serious blood clots in people with atrial fibrillation, a type of irregular heartbeat. It's also looking at how safe the new drug is.
For: Prevention of stroke or systemic embolism in atrial fibrillationFinland · Norway · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(20604 OCEANIC STROKE) A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
This study is looking for a new medicine called asundexian to help prevent strokes in people who have recently had a stroke or a mini-stroke. It compares this new medicine with a dummy pill to see if it works better and is safe.
For: Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attackSlovakia · Latvia · Hungary